Abstract:Intravenous (IV) iron-carbohydrate complexes are widely used nanoparticles (NPs) to treat iron deficiency anaemia, often associated with medical conditions such as chronic kidney disease, heart failure and various inflammatory conditions. Even though a plethora of physicochemical characterisation data and clinical studies are available for these products, evidence-based correlation between physicochemical properties of iron-carbohydrate complexes and clinical outcome has not fully been elucidated yet. Studies on other metal oxide NPs suggest that early interactions between NPs and blood upon IV injection are key to understanding how differences in physicochemical characteristics of iron-carbohydrate complexes cause variance in clinical outcomes. We therefore investigated the core-ligand structure of two clinically relevant iron-carbohydrate complexes, iron sucrose (IS) and ferric carboxymaltose (FCM), and their interactions with two structurally different human plasma proteins, human serum albumin (HSA) and fibrinogen, using a combination of cryo-scanning transmission electron microscopy (cryo-STEM), x-ray diffraction (XRD), small-angle x-ray scattering (SAXS) and small-angle neutron scattering (SANS). Using this orthogonal approach, we defined the nano-structure, individual building blocks and surface morphology for IS and FCM. Importantly, we revealed significant differences in the surface morphology of the iron-carbohydrate complexes. FCM shows a localised carbohydrate shell around its core, in contrast to IS, which is characterised by a diffuse and dynamic layer of carbohydrate ligand surrounding its core. We hypothesised that such differences in carbohydrate morphology determine the interaction between iron-carbohydrate complexes and proteins and therefore investigated the NPs in the presence of HSA and fibrinogen. Intriguingly, IS showed significant interaction with HSA and fibrinogen, forming NP-protein clusters, while FCM only showed significant interaction with fibrinogen. We postulate that these differences could influence bio-response of the two formulations and their clinical outcome. In conclusion, our study provides orthogonal characterisation of two clinically relevant iron-carbohydrate complexes and first hints at their interaction behaviour with proteins in the human bloodstream, setting a prerequisite towards complete understanding of the correlation between physicochemical properties and clinical outcome.

Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose

A comprehensive study of intravenous iron-carbohydrate nanomedicines: From synthesis methodology to physicochemical and pharmaceutical characterization

The pharmacology and safety profile of ferric carboxymaltose (Ferinject ® ): structure/reactivity relationships of iron preparations

Physicochemical and structural characterization of iron-sucrose formulations: a comparative study

Physicochemical and toxicological characterization of a new generic iron sucrose preparation

An Optimized Process for the Preparation of Aqueous Ferric Carboxymaltose: Synthesis and Structural Characterization

Iron-carbohydrate complexes treating iron anaemia: Understanding the nano-structure and interactions with proteins through orthogonal characterisation

Ferrous iron content of intravenous iron formulations

Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose

Interactions between Iron(III)-hydroxide Polymaltose Complex and Commonly Used Drugs

Dissimilar ferric derisomaltose formulations - In vitro comparisons between an originator and its intended similars

Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver.

Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products

Comparative Evaluation of Intestinal Absorption and Functional Value of Iron Dietary Supplements and Drug with Different Delivery Systems

Comparative in vitro and in vivo Evaluation of Different Iron Oxide-Based Contrast Agents to Promote Clinical Translation in Compliance with Patient Safety

Preparation, Characterization, Stability and Bioactivity of Fermented Tremella Polysaccharide-Fe3+ Complex

Sucrosomial® iron absorption studied by in vitro and ex-vivo models

Intestinal Absorption Study of a Granular Form of Ferric Pyrophosphate

Preparation and in Vitro Absorption Studies of a Novel Polysaccharide‑iron (III) Complex from Flammulina Velutipes.

Iron sucrose: assessing the similarity between the originator drug and its intended copies

The Story of Ferumoxytol: Synthesis Production, Current Clinical Applications and Therapeutic Potential